TP53 and cancer: Furthermore, in agreement with earlier observations3, we observed loss of the tumour suppressor genes PTEN and TP53 more frequently in ETS-positive cancers (TP53: 77% ETS+ versus 42% ETS−; PTEN: 66% ETS+ versus 45–54% ETS−).